APO Research
Talk to an analyst

APO RESEARCH · REPORT

Women's Health Care Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Women's Health Care Drugs Market Analysis and Forecast 2026-2032

1 January 2026199 pages

Choose your research edition.

Industry ResearchWomen's Health Care Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Women's Health Care Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Women's Health Care Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Women's Health Care Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Women's Health Care Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Women's Health Care Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Women's Health Care Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Women's Health Care Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Women's Health Care Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Women's Health Care Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Women's Health Care Drugs include Merck & Co, Mylan N.V., Lupin, Pfizer Inc., Ferring Pharmaceuticals, Bayer AG, Amgen, Allergan and Blairex Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Women's Health Care Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Women's Health Care Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Women's Health Care Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Women's Health Care Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Women's Health Care Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Women's Health Care Drugs revenue, projected growth trends, production technology, application and end-user industry.

Women's Health Care Drugs Segment by Company

Merck & Co

Mylan N.V.

Lupin

Pfizer Inc.

Ferring Pharmaceuticals

Bayer AG

Amgen

Allergan

Blairex Laboratories

Apothecus Pharmaceutical

Agile Therapeutics

Women's Health Care Drugs Segment by Type

Endometriosis

Postmenopausal Osteoporosis

Menopause

Hormonal Infertility

Polycystic Ovary Syndrome

Contraceptives

Others

Women's Health Care Drugs Segment by Application

Prescription Drugs

Non-prescription Drugs

Women's Health Care Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women's Health Care Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Women's Health Care Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women's Health Care Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Women's Health Care Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Women's Health Care Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Women's Health Care Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Women's Health Care Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Endometriosis Major Player Table 3. Postmenopausal Osteoporosis Major Player Table 4. Menopause Major Player Table 5. Hormonal Infertility Major Player Table 6. Polycystic Ovary Syndrome Major Player Table 7. Contraceptives Major Player Table 8. Others Major Player Table 9. Global Women's Health Care Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Prescription Drugs Major Player Table 11. Non-prescription Drugs Major Player Table 12. Women's Health Care Drugs Industry Trends Table 13. Women's Health Care Drugs Industry Drivers Table 14. Women's Health Care Drugs Industry Opportunities and Challenges Table 15. Women's Health Care Drugs Industry Restraints Table 16. Global Women's Health Care Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Women's Health Care Drugs Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Women's Health Care Drugs Market Share by Region (2021-2026) Table 19. Global Women's Health Care Drugs Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Women's Health Care Drugs Market Share by Region (2027-2032) Table 21. Global Women's Health Care Drugs Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Women's Health Care Drugs Revenue Market Share by Players (2021-2026) Table 23. Global Women's Health Care Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Women's Health Care Drugs Key Players Headquarters & Area Served Table 25. Global Women's Health Care Drugs Players, Product Type & Application Table 26. Global Women's Health Care Drugs Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Women's Health Care Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Women's Health Care Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Women's Health Care Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Women's Health Care Drugs Revenue Market Share by Type (2027-2032) Table 34. Global Women's Health Care Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Women's Health Care Drugs Revenue Market Share by Application (2021-2026) Table 38. Global Women's Health Care Drugs Revenue Market Share by Application (2027-2032) Table 39. Merck & Co Company Information Table 40. Merck & Co Business Overview Table 41. Merck & Co Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Merck & Co Women's Health Care Drugs Product Portfolio Table 43. Merck & Co Recent Development Table 44. Mylan N.V. Company Information Table 45. Mylan N.V. Business Overview Table 46. Mylan N.V. Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Mylan N.V. Women's Health Care Drugs Product Portfolio Table 48. Mylan N.V. Recent Development Table 49. Lupin Company Information Table 50. Lupin Business Overview Table 51. Lupin Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Lupin Women's Health Care Drugs Product Portfolio Table 53. Lupin Recent Development Table 54. Pfizer Inc. Company Information Table 55. Pfizer Inc. Business Overview Table 56. Pfizer Inc. Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Inc. Women's Health Care Drugs Product Portfolio Table 58. Pfizer Inc. Recent Development Table 59. Ferring Pharmaceuticals Company Information Table 60. Ferring Pharmaceuticals Business Overview Table 61. Ferring Pharmaceuticals Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Ferring Pharmaceuticals Women's Health Care Drugs Product Portfolio Table 63. Ferring Pharmaceuticals Recent Development Table 64. Bayer AG Company Information Table 65. Bayer AG Business Overview Table 66. Bayer AG Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Bayer AG Women's Health Care Drugs Product Portfolio Table 68. Bayer AG Recent Development Table 69. Amgen Company Information Table 70. Amgen Business Overview Table 71. Amgen Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Amgen Women's Health Care Drugs Product Portfolio Table 73. Amgen Recent Development Table 74. Allergan Company Information Table 75. Allergan Business Overview Table 76. Allergan Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Allergan Women's Health Care Drugs Product Portfolio Table 78. Allergan Recent Development Table 79. Blairex Laboratories Company Information Table 80. Blairex Laboratories Business Overview Table 81. Blairex Laboratories Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Blairex Laboratories Women's Health Care Drugs Product Portfolio Table 83. Blairex Laboratories Recent Development Table 84. Apothecus Pharmaceutical Company Information Table 85. Apothecus Pharmaceutical Business Overview Table 86. Apothecus Pharmaceutical Women's Health Care Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Apothecus Pharmaceutical Women's Health Care Drugs Product Portfolio Table 88. Apothecus Pharmaceutical Recent Development Table 89. Agile Therapeutics Company Information Table 90. Agile Therapeutics Business Overview Table 91. Agile Therapeutics Women's Health Care Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Agile Therapeutics Women's Health Care Drugs Product Portfolio Table 93. Agile Therapeutics Recent Development Table 94. North America Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 95. North America Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 96. North America Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 97. North America Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 98. North America Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. North America Women's Health Care Drugs Revenue by Country (2021-2026) & (US$ Million) Table 100. North America Women's Health Care Drugs Revenue by Country (US$ Million) & (2027-2032) Table 101. Europe Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 102. Europe Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 103. Europe Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Europe Women's Health Care Drugs Revenue by Country (2021-2026) & (US$ Million) Table 107. Europe Women's Health Care Drugs Revenue by Country (US$ Million) & (2027-2032) Table 108. China Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 109. China Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 110. China Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 111. China Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 113. Asia Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 114. Asia Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 115. Asia Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Women's Health Care Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Asia Women's Health Care Drugs Revenue by Region (US$ Million) & (2021-2026) Table 118. Asia Women's Health Care Drugs Revenue by Region (US$ Million) & (2027-2032) Table 119. SAMEA Women's Health Care Drugs Revenue by Type (2021-2026) & (US$ Million) Table 120. SAMEA Women's Health Care Drugs Revenue by Type (2027-2032) & (US$ Million) Table 121. SAMEA Women's Health Care Drugs Revenue by Application (2021-2026) & (US$ Million) Table 122. SAMEA Women's Health Care Drugs Revenue by Application (2027-2032) & (US$ Million) Table 123. SAMEA Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. SAMEA Women's Health Care Drugs Revenue by Country (2021-2026) & (US$ Million) Table 125. SAMEA Women's Health Care Drugs Revenue by Country (US$ Million) & (2027-2032) Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Women's Health Care Drugs Image Figure 2. Global Women's Health Care Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Women's Health Care Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Endometriosis Image Figure 5. Postmenopausal Osteoporosis Image Figure 6. Menopause Image Figure 7. Hormonal Infertility Image Figure 8. Polycystic Ovary Syndrome Image Figure 9. Contraceptives Image Figure 10. Others Image Figure 11. Global Women's Health Care Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Women's Health Care Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 13. Prescription Drugs Image Figure 14. Non-prescription Drugs Image Figure 15. Global Women's Health Care Drugs Market Size (US$ Million) & (2021-2032) Figure 16. Global Women's Health Care Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Women's Health Care Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Women's Health Care Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Women's Health Care Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Women's Health Care Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Women's Health Care Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Women's Health Care Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Women's Health Care Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Women's Health Care Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Women's Health Care Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Women's Health Care Drugs Revenue Share by Type (2021-2032) Figure 28. North America Women's Health Care Drugs Revenue Share by Application (2021-2032) Figure 29. North America Women's Health Care Drugs Revenue Share by Country (2021-2032) Figure 30. United States Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Women's Health Care Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Women's Health Care Drugs Revenue Share by Type (2021-2032) Figure 35. Europe Women's Health Care Drugs Revenue Share by Application (2021-2032) Figure 36. Europe Women's Health Care Drugs Revenue Share by Country (2021-2032) Figure 37. Germany Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Women's Health Care Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Women's Health Care Drugs Revenue Share by Type (2021-2032) Figure 47. China Women's Health Care Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Women's Health Care Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Women's Health Care Drugs Revenue Share by Type (2021-2032) Figure 50. Asia Women's Health Care Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Women's Health Care Drugs Revenue Share by Region (2021-2032) Figure 52. Japan Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Women's Health Care Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Women's Health Care Drugs Revenue Share by Type (2021-2032) Figure 60. SAMEA Women's Health Care Drugs Revenue Share by Application (2021-2032) Figure 61. SAMEA Women's Health Care Drugs Revenue Share by Country (2021-2032) Figure 62. Brazil Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Women's Health Care Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Endometriosis
  • Postmenopausal Osteoporosis
  • Menopause
  • Hormonal Infertility
  • Polycystic Ovary Syndrome
  • Contraceptives
  • Others
Applications
  • Prescription Drugs
  • Non-prescription Drugs
Companies covered
  • Merck & Co
  • Mylan N.V.
  • Lupin
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Bayer AG
  • Amgen
  • Allergan
  • Blairex Laboratories
  • Apothecus Pharmaceutical
  • Agile Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Women's Health Care Drugs Market by Type
  3. 1.2.1 Global Women's Health Care Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Endometriosis
  5. 1.2.3 Postmenopausal Osteoporosis
  6. 1.2.4 Menopause
  7. 1.2.5 Hormonal Infertility
  8. 1.2.6 Polycystic Ovary Syndrome
  9. 1.2.7 Contraceptives
  10. 1.2.8 Others
  11. 1.3 Women's Health Care Drugs Market by Application
  12. 1.3.1 Global Women's Health Care Drugs Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Prescription Drugs
  14. 1.3.3 Non-prescription Drugs
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Women's Health Care Drugs Market Dynamics
  1. 2.1 Women's Health Care Drugs Industry Trends
  2. 2.2 Women's Health Care Drugs Industry Drivers
  3. 2.3 Women's Health Care Drugs Industry Opportunities and Challenges
  4. 2.4 Women's Health Care Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Women's Health Care Drugs Market Perspective (2021-2032)
  2. 3.2 Global Women's Health Care Drugs Growth Trends by Region
  3. 3.2.1 Global Women's Health Care Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Women's Health Care Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Women's Health Care Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Women's Health Care Drugs Revenue by Players
  2. 4.1.1 Global Women's Health Care Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Women's Health Care Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Women's Health Care Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Women's Health Care Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Women's Health Care Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Women's Health Care Drugs Players, Product Type & Application
  8. 4.5 Global Women's Health Care Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Women's Health Care Drugs Market CR5 and HHI
  11. 4.6.3 2025 Women's Health Care Drugs Tier 1, Tier 2, and Tier 3
5 Women's Health Care Drugs Market Size by Type
  1. 5.1 Global Women's Health Care Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Women's Health Care Drugs Revenue Market Share by Type (2021-2032)
6 Women's Health Care Drugs Market Size by Application
  1. 6.1 Global Women's Health Care Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Women's Health Care Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Women's Health Care Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck & Co
  2. 7.1.1 Merck & Co Company Information
  3. 7.1.2 Merck & Co Business Overview
  4. 7.1.3 Merck & Co Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck & Co Women's Health Care Drugs Product Portfolio
  6. 7.1.5 Merck & Co Recent Developments
  7. 7.2 Mylan N.V.
  8. 7.2.1 Mylan N.V. Company Information
  9. 7.2.2 Mylan N.V. Business Overview
  10. 7.2.3 Mylan N.V. Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Mylan N.V. Women's Health Care Drugs Product Portfolio
  12. 7.2.5 Mylan N.V. Recent Developments
  13. 7.3 Lupin
  14. 7.3.1 Lupin Company Information
  15. 7.3.2 Lupin Business Overview
  16. 7.3.3 Lupin Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lupin Women's Health Care Drugs Product Portfolio
  18. 7.3.5 Lupin Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Women's Health Care Drugs Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Ferring Pharmaceuticals
  26. 7.5.1 Ferring Pharmaceuticals Company Information
  27. 7.5.2 Ferring Pharmaceuticals Business Overview
  28. 7.5.3 Ferring Pharmaceuticals Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Ferring Pharmaceuticals Women's Health Care Drugs Product Portfolio
  30. 7.5.5 Ferring Pharmaceuticals Recent Developments
  31. 7.6 Bayer AG
  32. 7.6.1 Bayer AG Company Information
  33. 7.6.2 Bayer AG Business Overview
  34. 7.6.3 Bayer AG Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer AG Women's Health Care Drugs Product Portfolio
  36. 7.6.5 Bayer AG Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Women's Health Care Drugs Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 Allergan
  44. 7.8.1 Allergan Company Information
  45. 7.8.2 Allergan Business Overview
  46. 7.8.3 Allergan Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Allergan Women's Health Care Drugs Product Portfolio
  48. 7.8.5 Allergan Recent Developments
  49. 7.9 Blairex Laboratories
  50. 7.9.1 Blairex Laboratories Company Information
  51. 7.9.2 Blairex Laboratories Business Overview
  52. 7.9.3 Blairex Laboratories Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Blairex Laboratories Women's Health Care Drugs Product Portfolio
  54. 7.9.5 Blairex Laboratories Recent Developments
  55. 7.10 Apothecus Pharmaceutical
  56. 7.10.1 Apothecus Pharmaceutical Company Information
  57. 7.10.2 Apothecus Pharmaceutical Business Overview
  58. 7.10.3 Apothecus Pharmaceutical Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Apothecus Pharmaceutical Women's Health Care Drugs Product Portfolio
  60. 7.10.5 Apothecus Pharmaceutical Recent Developments
  61. 7.11 Agile Therapeutics
  62. 7.11.1 Agile Therapeutics Company Information
  63. 7.11.2 Agile Therapeutics Business Overview
  64. 7.11.3 Agile Therapeutics Women's Health Care Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Agile Therapeutics Women's Health Care Drugs Product Portfolio
  66. 7.11.5 Agile Therapeutics Recent Developments
8 North America
  1. 8.1 North America Women's Health Care Drugs Revenue (2021-2032)
  2. 8.2 North America Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Women's Health Care Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Women's Health Care Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Women's Health Care Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Women's Health Care Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Women's Health Care Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Women's Health Care Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Women's Health Care Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Women's Health Care Drugs Revenue by Country
  11. 8.6.1 North America Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Women's Health Care Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Women's Health Care Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Women's Health Care Drugs Revenue (2021-2032)
  2. 9.2 Europe Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Women's Health Care Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Women's Health Care Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Women's Health Care Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Women's Health Care Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Women's Health Care Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Women's Health Care Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Women's Health Care Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Women's Health Care Drugs Revenue by Country
  11. 9.6.1 Europe Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Women's Health Care Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Women's Health Care Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Women's Health Care Drugs Revenue (2021-2032)
  2. 10.2 China Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Women's Health Care Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Women's Health Care Drugs Revenue by Type (2027-2032)
  5. 10.3 China Women's Health Care Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Women's Health Care Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Women's Health Care Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Women's Health Care Drugs Revenue by Application (2027-2032)
  9. 10.5 China Women's Health Care Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Women's Health Care Drugs Revenue (2021-2032)
  2. 11.2 Asia Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Women's Health Care Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Women's Health Care Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Women's Health Care Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Women's Health Care Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Women's Health Care Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Women's Health Care Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Women's Health Care Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Women's Health Care Drugs Revenue by Country
  11. 11.6.1 Asia Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Women's Health Care Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Women's Health Care Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Women's Health Care Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Women's Health Care Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Women's Health Care Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Women's Health Care Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Women's Health Care Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Women's Health Care Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Women's Health Care Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Women's Health Care Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Women's Health Care Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Women's Health Care Drugs Revenue by Country
  11. 12.6.1 SAMEA Women's Health Care Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Women's Health Care Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Women's Health Care Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst